Literature DB >> 21649800

A survey of the outcome of prophylaxis, on-demand or combined treatment in 20-35 year old men with severe haemophilia in four European countries.

D Noone, B O'Mahony, L Prihodova.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21649800     DOI： 10.1111/j.1365-2516.2011.02582.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  6 in total

1.  Prophylaxis in haemophilia should be life-long.

Authors:  Mike Makris
Journal:  Blood Transfus       Date:  2012-02-13       Impact factor: 3.443

Review 2.  Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.

Authors:  Scott D Grosse; Shraddha S Chaugule; Joel W Hay
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-01-14       Impact factor: 2.217

3.  The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia.

Authors:  M W Skinner; C Chai-Adisaksopha; R Curtis; N Frick; M Nichol; D Noone; B O'Mahony; D Page; J S Stonebraker; A Iorio
Journal:  Pilot Feasibility Stud       Date:  2018-02-27

4.  Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A.

Authors:  Parth Vashi; Katharine Batt; Robert Klamroth; Maria Elisa Mancuso; Renata Majewska; Andreas Tiede; Lorenzo Giovanni Mantovani
Journal:  J Blood Med       Date:  2021-11-01

5.  Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample.

Authors:  Karissa Johnston; Jayson M Stoffman; Alexis T Mickle; Robert J Klaassen; Demitri Diles; Shade Olatunde; Lina Eliasson; Roxana Bahar
Journal:  Patient Prefer Adherence       Date:  2021-06-24       Impact factor: 2.711

6.  Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study.

Authors:  Angela L Forsyth; Michelle Witkop; Angela Lambing; Cesar Garrido; Spencer Dunn; David L Cooper; Diane J Nugent
Journal:  Patient Prefer Adherence       Date:  2015-10-29       Impact factor: 2.711
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.